Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: October 31, 2026
0
Views
0
Downloads
Authors
A real-world experience on dose reduction of ibrutinib in chronic lymphocytic leukemia is reported.
Downloads
Download data is not yet available.
Citations
1. Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28.
2. Lee P, Kistler KD, Douyon L, Volodarsky R, Young A, Karve S, Challagulla S. Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Drugs Real World Outcomes. 2023 Mar;10(1):11-22. doi: 10.1007/s40801-022-00332-4. Epub 2022 Dec 19.
3. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
4. Moreno C, Delgado J, Byrd JC, Zvagelsky WL, Suzuki S, Hsu E, James DF, Montserrat E. Changes in clinical stage identify patients with CLL and different outcomes within iwCLL partial response: RESONATE study. Br J Haematol. 2019 Apr;185(1):148-150. doi: 10.1111/bjh.15397. Epub 2018 May 31.
5. JZ Hou, K Ryan, S Du, BS Fang, SM. Marks, R Page, E Peng, K Szymanski, S Winters, H Le. Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings. Blood, Volume 136, Supplement 1, 2020, Pages 12-13, ISSN 0006-4971, https://doi.org/10.1182/blood-2020-139951
6. Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020 May;9(10):3390-3399. doi: 10.1002/cam4.2998. ePub 2020 Mar 18.
7. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.
8. Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, Patten PEM, Grosicki S, McCarthy H, Offner F, Szafer-Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps TJ. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176. doi: 10.1182/blood.2024028205
9. CR Frei, H Le, D McHugh, C Elesinmogun, S Galley, K Franklin, J Tavera, MJ Martinez, DJ Gregorio, S Ananth, R Uribe, P Surapaneni, MR Espinoza-Gutarra, M Song, X Jones, C Teng, OO Obodozie-Ofoegbu, Z Nooruddin. Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting. Blood, Volume 134, Supplement 1, 2019, Page 795, ISSN 0006-4971, https://doi.org/10.1182/blood-2019-122434.
10. C Hardy-Abeloos, C Pinotti, J Gabrilove. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020 Jun 5;13(1):66. doi: 10.1186/s13045-020-00870-w.
11. Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020 May;9(10):3390-3399. doi: 10.1002/cam4.2998. Epub 2020 Mar 18.
12. Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11.
13. Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019 Jul;60(7):1650-1655. doi: 10.1080/10428194.2018.1554862. Epub 2019 Jan 2.
14. M Shadman, S Karve, S Patel, A Rava, H Sun, A Howarth, S Tomicki, BP Srivastava, DM Stephens. Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, Volume 142, Supplement 1,2023, Page 269, ISSN 0006-4971, https://doi.org/10.1182/blood-2023-181774.
15. SCORE2 working group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
16. X Lu, B Emond, Z Ding, P Lefebvre, MH Lafeuille, H Mavani, ZP Qureshi, N Ghosh. Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L). Journal of Clinical Oncology 2023 41:16_suppl, 7537-7537.
17. Ghosh N, Wang R, Qureshi ZP, Ding Z, Lafeuille MH, Emond B, Moore B, He J, Bokun A, Mavani H, Rogers KA. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation. Blood Neoplasia. 2024 Jun 10;1(3):100022. doi: 10.1016/j.bneo.2024.100022.
18. Martínez Pradeda A, Feijoo Vilanova P, Fernández Gabriel E, Giménez Arufe V, Vale López AM, Suanzes-Hernández J, Margusino-Framiñán L, Noriega Concepción V. Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes. Ann Pharmacother. 2026 Jan;60(1):23-35. doi: 10.1177/10600280251334133. Epub 2025 May 24.
19. Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, Franceschini E, Saifan C, Bacchus S, Roeker L, Stephens DM. Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2025 Jan;66(1):44-53. doi: 10.1080/10428194.2024.2402814.
20. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.
How to Cite
“Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026090. doi:10.4084/MJHID.2026.090.
Copyright (c) 2026 Roberta Laureana
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
